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Abstract
The study of saliva O-glycosylation is receiving increasing attention due to the potential of
glycans for disease biomarkers, but also due to easy access and non-invasive collection of
saliva as biological fluid. Saliva is rich in glycoproteins which are secreted from the blood-
stream or produced by salivary glands. Mucins, which are highly O-glycosylated proteins,
are particularlyabundant in human saliva. Their glycosylation is associated with blood
group and secretor status, and represents a reservoir of potential disease biomarkers. This
study aims to analyse and compareO-glycans released fromwhole humanmouth saliva
collected 3 times a day from a healthy individual over a 5 days period.O-linked glycans
were released by hydrazinolysis, labelled with procainamide and analysed by ultra-high per-
formance liquid chromatography with fluorescence detection (UHPLC-FLR) coupled to
electrospray ionizationmass spectrometry (ESI-MS/MS). The sample preparationmethod
showed excellent reproducibility and can therefore be used for biomarker discovery. Our
data demonstrates that the O-glycosylation in human saliva changes significantly during the
day. These changes may be related to changes in the salivary concentrations of specific
proteins.
Introduction
Saliva is a unique fluid that lubricates and buffers the oral cavity [1–2]. It protects the oral cav-
ity frommicrobial attack involving both the innate and acquired immune surveillances. Saliva
is a structurally very complex secretion containing components from a variety of glands such
as the parotid, submaxillary, sublingual and submandibular glands and someminor glands in
the lip, cheek, tongue and palate [3]. Saliva contains a wide spectrumof microbes, epithelial
cells, proteins/peptides, electrolytes, hormones, nasal and bronchial secretions and serum
product [4–7].
Saliva contains many glycoproteins, some of which are highly glycosylated (such as MUC5B
and MUC7) as well as salivary agglutinin, secretory immunoglobulinA (sIgA), lactoferrin,
amylase and proline-rich glycoproteins [8]. Mucins are dominant compounds in human saliva
and play an important role in the maintenance of oral health and protection of teeth as part of
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the first line oral defence [9–10]. Many glycoproteins bind to a variety of bacteria and either
aid or prevent adherence of bacteria to mucosal and tooth surfaces or lubricate tooth surfaces
and possibly protect proteins from proteolytic attack [11].
Bacteria usually have a net negative surface charge and therefore tend not to bind directly to
negatively charged mucins. Instead, they may interact through bridging reagents involving
divalent cations such as Ca2+ ions. However, many bacteria express cell surface proteins (lec-
tins) that specifically recognize oligosaccharides present on the salivarymucins. In this manner
salivarymucins are bound by multiple bacteria resulting in agglutination. Removal of the ter-
minal sialic acids from the oligosaccharide side chains of salivarymucins was found to abolish
agglutination of oral streptococci, indicating that the bacterial lectin has specificity for sialic
acids [12]. Salivary agglutinin, a highly glycosylated protein frequently associated with other
salivary proteins and with secretory immunoglobulinA (IgA), is one of the main salivary com-
ponents responsible for bacteria agglutination [13].
Secretory IgA is the most abundant humoral immunologic component of saliva. It can neu-
tralize viruses, bacteria, and enzyme toxins. It binds bacterial antigens and is able to aggregate
bacteria and inhibit their adherence to oral tissues [14–15]. Other immunologic components,
such as IgG and IgM, occur in lower quantity and probably originate from gingival fluid [16].
Salivary composition shows associations with various oral and systemic diseases [17–22],
and significant age- or sex-related differences have been reported with respect to genomic [23,
24]and proteomic expression levels [25–27].
Recently, interest in glycomics (the study of the spectrumof glycans expressed in a biologi-
cal system) has increased due to the potential clinical utility of glycans as disease biomarkers
[28]. Glycosylation of proteins is a complex and common post-translational modification
influencingmany biological functions. There are two main types of glycosylation found in
eukaryotes:N-glycosylation and O-glycosylation. On salivary glycoproteins, N-glycans are
structurally diverse encompassing the highmannose, hybrid and complex N-glycan subclasses.
The O-glycans comprise various O-glycan core types, with optionally fucoses in different link-
ages as well as sialylation and sulphation [29, 30]. It has been reported that salivaryMUC5B
contains O-glycans which vary between individuals and that some of this variation is related to
blood group and secretor status [31]. Also O-glycans attached to salivaryMUC7 showed
changes in the patients with recurrent aphthous stomatitis (RAS). Patients with RAS have less
complex O-glycans, suggesting that there are bacterial oligosaccharide-degradingenzymes that
reduce glycan complexity [32].
Human saliva proteomics has proven to be a novel approach in the search for protein bio-
markers for detection of diseases [31], including cancer, autoimmune diseases, viral diseases,
bacterial diseases, cardiovascular diseases, and human immunodeficiencyvirus (HIV) [2, 33].
It has become clear that proteomic composition of saliva can reflect the pathological as well as
physiological state [34, 35]. Recently, a growing number of proof-of-principle assays have been
established using saliva to monitor diseases or bodily conditions such as infection, immune
responses to viral infections, systemic levels of drugs, and the detection of illicit drug use [36].
Saliva profiling over the course of disease progression could reveal potential biomarkers indica-
tive of different stages of diseases, which may be useful in medical diagnostics. This follows
from several studies showing that glycosylation patterns in other body fluids such as plasma
correlate with progression of certain diseases, including inflammatory conditions and sub-
classes of diabetes [37–39].
Here, we describe the evaluation of longitudinal changes in salivaryO-glycosylation profiles
using samples collected 3 times a day over a 5 days period. The O-glycans were released by
hydrazinolysis using a recently developed improved protocol [40] and fluorescently labelled
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with procainamide, followed by HILIC-UHPLC-FLR-ESI-MS analysis. The chosen techniques
proved to be suitable to demonstrate major changes in the salivaryO-glycome during the day.
Materials andMethods
Materials
All reagents and kits for O-glycan release, labelling and clean-up were from Ludger Ltd.
(Oxford, UK). Centrifugal filter devices with a molecular weight cut-off (MWCO) membrane
of 10 kDa were obtained from Fisher ScientificUK (Leicestershire, UK). Acetonitrile (Romil;
190 SpS for UV/ gradient quality) was obtained from Charlton Scientific (Charlton, Oxon,
UK). Fetuin glycoprotein was from Ludger Ltd and all other reagents were obtained from
Sigma-Aldrich (Dorset, UK). Procainamide labelling was performed on a Hamilton Microlab
STARLet liquid-handling robotic platform.
Collection of saliva
Whole unstimulated saliva (5 mL) was collected 3 times a day over a 5 days period from two
human donors. Volunteers were asked to rinse their mouths with water for 30 seconds to
remove any food particles. Donors were also asked to retain from eating 2 h prior to collection
[3]. PBS supplemented with protease inhibitor cocktail (2 mL, AEBSF at 2 mM, Aprotinin at
0.3 μM, Bestatin at 116 μM, E-64 at 14 μM, Leupeptin at 1 μM and EDTA at 1 mM) and antibi-
otic-antimycotic mixture containing 10,000 units penicillin, 10 mg streptomycin and 25 μg
amphotericin B per mL were added to each saliva sample. The saliva samples were clarified by
centrifugation at 3000 x g at 4°C for 20 min to remove cellular debris. The supernatant was
concentrated [29] using centrifugal filter device (10 kDaMWCOmembrane). Samples were
then stored at -20°C until required for further experimentation.
Release of O-glycans by hydrazinolysis
The saliva samples and fetuin glycoprotein (used as a positive control) were buffer exchanged
into 0.1% TFA prior to hydrazinolysis as describedpreviously [40]. Samples were transferred
to glass vials and dried down for 16 h by vacuum centrifugation prior to the addition of
hydrazine.
Fetuin and saliva samples were incubated with 450 μL anhydrous hydrazine (Ludger) at
60°C for 6 h [41, 42]. Excess hydrazine was removed by centrifugal evaporation. The samples
were placed on ice for 20 min (0°C) and were re-N-acetylated by addition of 0.1 M sodium
bicarbonate solution (200 μL) and acetic anhydride (21 μL). Samples were cleaned up by pass-
ing them through the Ludger Clean CEX cartridges (Ludger). The O-glycans were eluted off
the cartridges using water (3 x 0.5 mL). Eluates were dried by vacuum centrifugation prior to
fluorescent labelling.
Procainamide labelling
Of the released O-glycans, 40% was fluorescently labelled with procainamide as describedpre-
viously [43] using Ludger procainamide glycan labelling kit containing 2-picoline borane.
Briefly, samples in 10 μL of water were mixed with 10 μL of procainamide labelling solution
and incubated at 65°C for 1 h. The samples were evaporated to dryness by vacuum centrifuga-
tion and re-suspended in water (100 μL) for further analysis.
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LC-ESI-MSandMS/MS analysis
Procainamide labelled samples were analysed by HILIC-UHPLC-ESI-MSwith fluorescence
detection. Samples were injected in 10% water/90% acetonitrile (injection volume 25 μL) onto
an ACQUITYUPLC BEH-Glycan 1.7 μm, 2.1 x 150 mm column at 60°C on a Ultimate 3000
UHPLC instrument with a fluorescence detector (λex = 310nm, λem = 370nm; Thermo Scien-
tific). The running conditions used were: Solvent A was 50 mM ammonium formate pH 4.4
made from Ludger Stock Buffer (Ludger), and solvent B was acetonitrile. Gradient conditions
were: 0 to 10 min, 90% B; 10 to 95 min, 90 to 57% B at flow rate 0.4 mL/min; 95 to 98 min, 57
to 0% B at a flow rate of 0.4 mL/min; 98 to 99 min, 0% B at a flow rate of 0.25 mL/min; 99 to
100 min, 0% B at a flow rate of 0.25 mL/min. 100 to 103 min, 90% B at a flow rate 0.25 mL/
min; 103 to 115 min, 90% B at a flow rate 0.4 mL/min. The UHPLC system was coupled on-
line to an Amazon Speed ETD (Bruker Daltonics, Bremen, Germany) with the following set-
tings: source temperature 250°C, gas flow 10 L/min; Capillary voltage 4500 V; ICC target
200,000; maximum accumulation time 50 ms; rolling average 2; number of precursors ions
selected 3, release after 0.2 min; Positive ion mode; Scanmode: enhanced resolution; mass
range scanned, 200–1600; Target mass, 900. A glucose homopolymer ladder (Ludger), labelled
with procainamide was used as a system suitability standard as well as an external calibration
standard for GU allocation [44].
Sample variation
Using in-house developed scripts, raw HILIC chromatograms for 2 individuals were exported
from Chromeleon 7.1 (Dionex, USA) and aligned by applying the least variance linear fit
through the highest data points observedwithin ± 0.25 min window around retention times
22.33, 27.13, 28.70, 29.28, 32.43 and 33.64 min. Then, for each chromatogram independently,
the areas of the 7 most abundant peaks were integrated centering at 20.55 min (within a ± 0.5
min window), 22.26 (± 0.35), 23.99 (± 0.35), 24.74 (± 0.5), 27.17 (± 0.35), 32.39 (± 0.25) and
33.57 (± 0.25). The obtained peak areas were normalized to the total area sum within each
chromatogram, and expressed in stripplot format using R version 3.1.2 (R Foundation for sta-
tistical computing, Vienna Austria).
Ethics statement
The Research Ethic Committee (NHS Health Research Authority, Surrey Borders REC Lon-
don, UK) granted approval for this study with all participants giving written, informed consent
(REC 16/LO/0883; IRAS project ID: 203515).
Results and Discussion
Evaluation of method repeatability
The release and recovery of O-glycans still remains very challenging because there is no univer-
sal enzyme available for O-glycan release from glycoproteins. Therefore, the current best meth-
ods for universal O-glycan release rely on rather harsh chemistry. Over the last two decades a
number of chemical methods for O-glycan removal have been developed, including reductive
and non-reductive β-elimination and hydrazinolysis [45]. It has been reported that the most
suitable method for universal O-glycan release in their non-reduced form in high yields is
hydrazinolysis [41]. We decided to use this technique to release O-glycans from human saliva
because the releasedO-glycans contain free reducing termini allowing further derivatization
with fluorescent tags and analysis by HPLC-basedmethods [40, 46].
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First, we investigated whether the sample preparation and glycan release method is suitable
for saliva samples. Using fetuin glycoprotein and a saliva reference sample collected from a sin-
gle individual as positive controls, we evaluated the O-glycan preparation and O-mode hydra-
zinolysis. Triplicates of bovine fetuin and saliva samples were buffer exchanged into 0.1% TFA
prior to release [40]. The O-glycans were released using anhydrous hydrazine, labelled with
procainamide and analysed by HILIC-UHPLCwith fluorescence detection providing good gly-
can separation, coupled to ESI-MS and MS/MS providing glycan composition.
The HILIC-UHPLC profiles for triplicate releases of O-glycans from fetuin sample (Fig 1)
were consistent with previously published data [46, 47]. The fetuin profiles contain 6 main
peaks corresponding to: core 1, Galβ1–3GalNAc (peak 1); monosialylated core 1 O-glycans,
Neu5Acα2–3Galβ1–3GalNAc (peak 3); and Neu5Acα2–6(Galβ1–3)GalNAc (peak 4); disialy-
lated core 1 O-glycan, Neu5Acα2–3Galβ1–3(Neu5Acα2–6)GalNAc (peak 5); and disialylated
core 2 O-glycan, Neu5Acα2–3Galβ1–3(Neu5Acα2–3Galβ1–4GlcNAcβ1–6)GalNAc (peak 6).
The peeled product Neu5Acα2–3Gal (peak 2, Fig 1) was also detected. To confirm the identity
of observedpeaks (peaks 1–6, Fig 1) the procainamide labelledO-glycans were characterized
by ESI-MS/MS. The results from HILIC-UHPLC coupled to ESI-MS/MS are summarised in S1
Table and an example of fragmentation analysis of procainamide labelledO-glycans is shown
in S1 Fig. The glycan peak areas for each release were very similar with the standard deviation
between the samples below 5.5% for all peaks (Fig 2).
Fig 1. HILIC-UHPLC profiles for procainamide labelledO-glycans released in triplicate from fetuin.The following symbols are used to depict
glycan structures [57]: open diamond = galactose; closed diamond= N-acetylgalactosamine; closed square = N-acetylglucosamine; closed star = N-
acetyleneuraminic acid; dashed line, α-linkage; solid line, β-linkage.
doi:10.1371/journal.pone.0162824.g001
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The robustness of the O-glycosylation analysis method was also tested on the saliva
standard. The O-glycans were released by anhydrous hydrazine, labelled with procainamide
and analysed by HILIC-UHPLC-ESI-MS with fluorescence detection. The HILIC-UHPLC
profiles for triplicate releases of O-glycans from whole saliva sample are shown in Fig 3.
As the profiles were very complex we selected a subset of 18 peaks for comparison. These
peaks were analysed by ESI-MS/MS to determine O-glycan composition. The glycan peak
areas for selected peaks were very similar with the standard deviation between the samples
below 1% (Fig 4). Thus, O-mode hydrazinolysis, procainamide labelling systems and UHPL-
C-ESI-MS/MS analysis are highly reproducible and suitable for the analysis of human saliva
samples.
Fig 2. O-glycanspatternsobtained from bovine fetuin. Sampleswerewashedwith 0.1%TFA followed by hydrazinolysis, procainamide
labellingandHILIC-UHPLC analysiswith fluorescence detection.The average abundance of the O-glycans was determined onmultiple days.
Symbols are as in Fig 1.
doi:10.1371/journal.pone.0162824.g002
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Longitudinal analysis of O-glycans from human saliva
O-glycans were released from saliva (collected 3 times a day over a 5 days period from 2 indi-
viduals) by hydrazinolysis after acidic wash, labelled with procainamide and analysed by
UHPLC-ESI-MS/MS.Only one sample was taken through ESI-MS/MS analysis. As the
obtained HILIC profiles were very complex we selected a subset of 27 peaks for comparison
and detailed analysis by ESI-MS/MS (S2 Fig). A broad range of O-glycan compositions were
detected in the samples and although there was some overlap in LC traces, the sample profiles
showed prominent differences. The observedmolecularmasses and compositions of 27
selected structures (Fig 5) are summarised in Table 1.
The O-glycans displayed a heterogenous mixture of neutral and acidic oligosaccharides and
most of the structures were fucosylated. The MS/MS fragmentation data of procainamide
labelledO-glycans contained diagnostic fragment ions characteristic of core type or blood
group epitope consistent with previously reported data [29, 21, 48, 49]. The O-glycans carried
the blood group H-epitopes Fucα1-2Galβ1 (diagnostic structure: Fuc-Hex) which is usually
modified by a single monosaccharide residue (Galα1-3- or GalNAcα1-3-) and determines
ABO blood groups [31, 50, 51]. The O-glycans found in this study were released from whole
saliva from an individual of blood group A. The terminal structures of glycans 13 and 18
(Fig 5, Table 1) have a HexNAc attached to (Fuc)-Hex-HexNAc-Proc (blood group H-epitope),
suggesting expression of blood group A antigen GalNAcα1-3(Fucα1–2)Galβ1- on saliva glyco-
proteins. The presence of ABO blood group specific epitopes matching the blood group status
suggest that the saliva donor is secretor.
Derived glycosylation features such as galactosylation and fucosylationwere calculated for
the selectedO-glycan peaks to analyse the range of variability. Firstly, we compared levels of
galactosylation (Fig 6B). A pronounced decrease in galactosylation (from 91% on the first day
to 78% on the fifth day) was observed for the samples collected in the morning. For the samples
Fig 3. HILIC-UHPLCO-glycanprofiles of saliva reference sample collected from a single individual in
themorning.Samplewas buffer exchange into 0.1% TFA, and the O-glycans were released in triplicateby
hydrazinolysis followed by procainamide labelling and HILIC-UHPLC analysis with fluorescence detection.
doi:10.1371/journal.pone.0162824.g003
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collected in the afternoon or evening, variation was also high (between 83% and 94% for after-
noon collection and 76% and 93% for evening collection).
Next we looked at changes in fucosylation for the samples collected three times a day during
a 5 days period (Fig 6C). High biological variation was observedboth intra-day and inter-day
with fucosylation levels ranging from 43% to 57%.
We also looked at changes in sialylation. Significant variation (between 5% and 13%)
between samples collected at different points of the day during the 5 days periodwas observed
(Fig 6E).
The peak alignment across all HILIC chromatograms from two individuals shows that the
individuals differ in relative peak abundance, while displaying similar variation within each
peak (S3C Fig).
Fig 4. O-glycanpatternsobtained from triplicate releases from saliva sample collected in themorning.Samples were washed with 0.1%
TFA followed by hydrazinolysis, procainamide labelling and HILIC-UHPLC analysis with fluorescence detection. 18 O-glycan structures were
selected for comparison.
doi:10.1371/journal.pone.0162824.g004
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The main aim of this study was to analyse and compare entire O-glycan populations
released form whole human saliva samples collected 3 times a day over a 5 days period.Our
results highlighted that there is extensive natural variation in the salivaryO-glycosylation. Both
the intra-day and the inter-day variation appeared to be high.
We used whole human saliva because the wide spectrumof compounds (including glyco-
proteins) present in saliva may provide information for potentially important biomarkers
and it has been reported that 30% of blood proteins are also present in saliva [52]. Also
changes in O-glycans have been associated with different disease states [53, 54]. It has been
previously published that the variation in salivaryMUC5B glycosylation is high and depen-
dent on blood group or secretor status [31]. Likewise, one may expect that salivary O-glyco-
sylation, along with dynamic changes in composition of other salivary analytes may depend
on diet, lifestyle and inflammatory responses in the mucus layer, although additional studies
will be necessary to study this. One of the biggest advantages of saliva is easy collection,
Fig 5. HILIC-UHPLC profile of saliva O-glycanpatterns.Samples were collected in days 1–5 in themorning.Samples were buffer exchanged into
0.1% TFA, and the O-glycans were released by hydrazinolysis followed by procainamide labelling and HILIC-UHPLC analysis with fluorescence
detection.
doi:10.1371/journal.pone.0162824.g005
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storage and transportation. Donation is non-invasive, stress-free and it does not require
highly-trained personnel [55].
Conclusions
Our study showed that the composition and relative abundance of the O-glycans in human
saliva changes considerably during the day. This is an interesting observation and should be
taken into account when evaluating salivaryO-glycosylation e.g. for its diagnostic biomarker
potential.
The changes in the specificO-glycan types within one day as well as between days may be
caused by changes in the salivary concentrations of specific proteins, but may likewise be attrib-
uted to changes in protein-specific glycosylation profiles. It may, therefore, make sense to fol-
low-up the current study and assess the glycosylation of one of the mucins abundantly present
in saliva with respect to its longitudinal robustness and biomarker potential. Mucins found in
saliva have high turnover rates and respond quickly to altered conditions within the body [32,
Table 1. Mass spectrometric data for selected27 O-glycansobtained from human saliva.
UHPLC Peak
Id
Average GU (PROC) HILIC-UHPLC-ESI-MS
Composition Calculated [m/z]+ Registered [m/z]+ Probable structures
Hex (H) HexNAc (N) Fucose (F) Neu5Ac (S)
1 1.40 0 1 1 0 587.38 587.32 -
2 1.51 1 0 1 0 546.38 546.30 F-H-PROC
3 1.63 0 2 1 0 791.45 790.41 F-N-N-PROC
4 1.66 1 1 0 0 603.39 603.32 H-N-PROC
5 1.81 1 1 1 0 749.45 749.38 F-H-N-PROC
6 2.21 1 1 1 0 749.45 749.38 F-H-N-PROC
7 2.30 1 1 0 1 894.48 894.42 S-H-N-PROC
8 2.45 1 2 0 0 806.46 806.40 N-(H)-N-PROC
9 2.48 1 2 0 0 806.46 806.40 N-(H)-N-PROC
10 2.57 1 1 2 0 895.5 895.44 S-(S-H)-N-ROC
11 2.61 1 2 1 0 952.51 952.46 N-(S-H)-N-ROC
12 2.64 1 3 0 0 1010.53 1009.48 H-N-(N)-N-ROC
13 2.82 1 2 1 0 952.51 952.46 N-(F)-H-N-ROC
14 2.87 2 2 0 0 969.5 968.46 -
15 2.98 1 1 0 1 894.48 894.42 S-(H)-N-PROC
16 3.05 1 3 1 0 1156.59 1155.54 S-H-N-(N)-N-PROC
17 3.28 2 2 0 0 968.52 968.46 H-(H-N)-N-PROC
18 3.41 1 2 2 0 1098.59 1098.52 N-(F)-H-(F)-N-PROC
19 3.69 3 1 0 0 927.1 927.43 -
20 3.73 2 2 1 0 1114.59 1114.51 H-N-(F-H)-N-PROC
21 3.78 2 2 1 0 1114.59 1114.51 H-N-(F-H)-N-PROC
22 3.85 2 2 0 1 1259.64 1259.55 S-H-N-H-N PROC
23 3.89 2 2 1 0 1114.59 1114.51 H-N-(F-H)-N-PROC
24 3.97 2 2 1 0 1114.58 1114.51 N-H-N-(F)-H-PROC
25 4.18 3 2 0 0 1130.58 1130.51 -
26 4.31 2 2 2 0 1260.65 1260.57 F-H-N-(F-H)-N-PROC
27 4.40 2 2 1 1 [703.00]2+ [703.31]2+ F-H-N-(S-H)-
N-PROC
doi:10.1371/journal.pone.0162824.t001
Variation of HumanSalivaryO-Glycome
PLOSONE | DOI:10.1371/journal.pone.0162824 September 9, 2016 10 / 15
Fig 6. Saliva O-glycosylationvariation during collection.Several differences in saliva O-glycosylation between different collection times and days
can be observedwith respect to (A) neutral glycans, (B) galactosylation, (C) fucosylation, (D) difucosylation, (E) monosialylation. Data for the technical
replicates corresponds to the saliva reference sample collected from a single individual and analysed during evaluation of method repeatability and
robustness.
doi:10.1371/journal.pone.0162824.g006
Variation of HumanSalivaryO-Glycome
PLOSONE | DOI:10.1371/journal.pone.0162824 September 9, 2016 11 / 15
56]. Mucins and their O-glycans affect a range of aspects of oral health and their changes in the
response to the infection and inflammation [32].
Supporting Information
S1 Table. Summary of O-glycan structures from fetuin with GU values, average relative
abundance and mass values.
(PDF)
S1 Fig. MS/MS characterizationof procainamide labelled fetuin O-glycan following online
HILIC-UHPLC. (a) MS/MS characterization of the glycan eluting at retention time equivalent
to that of GU 4.91. (b) Fragmentation scheme of the [M+2H]2+ ion atm/z 775.84. The nomen-
clature used for fragmentation is based on literature [58].
(PDF)
S2 Fig. Fluorescence,MS andMS/MS traces of saliva O-glycanpatterns.One sample, col-
lected from individual 1 at day 1 in the morning, was used for in-depth analysis. (a) HILIC-FLR
trace (FLR); (b) base peak chromatogram (BPC); (c) total ion chromatogram (TIC).
(PDF)
S3 Fig. Comparison of HILIC-UHPLCO-glycan profiles of saliva samples collected from
two individuals.The 7 peaks labelled with asterisks correspond to signals suitable for align-
ment and integration. (a) Saliva sample from individual 1 collected at day 1 in the morning; (b)
Saliva sample from individual 2 collected at day 1 in the morning; (c) Comparison between
individual 1 and 2 of the variation across time within 7 O-glycans measured by HILI-
C-UHPLC. After chromatogram alignment, the signals were integrated and the obtained areas
normalized to the total area sum. The individuals show to differ in relative peak abundance,
while displaying similar variation within each peak.
(PDF)
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